JP2002518347A5 - - Google Patents

Download PDF

Info

Publication number
JP2002518347A5
JP2002518347A5 JP2000554401A JP2000554401A JP2002518347A5 JP 2002518347 A5 JP2002518347 A5 JP 2002518347A5 JP 2000554401 A JP2000554401 A JP 2000554401A JP 2000554401 A JP2000554401 A JP 2000554401A JP 2002518347 A5 JP2002518347 A5 JP 2002518347A5
Authority
JP
Japan
Prior art keywords
shows
antibodies
val
psa
prt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000554401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB1999/001115 external-priority patent/WO1999065523A1/en
Publication of JP2002518347A publication Critical patent/JP2002518347A/ja
Publication of JP2002518347A5 publication Critical patent/JP2002518347A5/ja
Pending legal-status Critical Current

Links

JP2000554401A 1998-06-15 1999-06-15 前立腺癌治療のための免疫療法組成物および方法 Pending JP2002518347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8928198P 1998-06-15 1998-06-15
US60/089,281 1998-06-15
PCT/IB1999/001115 WO1999065523A1 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
JP2002518347A JP2002518347A (ja) 2002-06-25
JP2002518347A5 true JP2002518347A5 (enExample) 2007-01-18

Family

ID=22216751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554401A Pending JP2002518347A (ja) 1998-06-15 1999-06-15 前立腺癌治療のための免疫療法組成物および方法

Country Status (9)

Country Link
US (3) US6881405B2 (enExample)
EP (1) EP1085905B1 (enExample)
JP (1) JP2002518347A (enExample)
AT (1) ATE480566T1 (enExample)
AU (1) AU768002B2 (enExample)
CA (1) CA2328504A1 (enExample)
DE (1) DE69942742D1 (enExample)
IL (1) IL139700A (enExample)
WO (1) WO1999065523A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
CZ302801B6 (cs) 1999-01-13 2011-11-16 Igeneon Krebs-Immuntherapie Forschungs Und Entwicklungs-Ag Použití protilátky namírené proti antigenu bunecné membrány Ep-CAM pro výrobu farmaceutického prostredku
IL152747A0 (en) * 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
WO2003086041A2 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
WO2004035003A2 (en) * 2002-10-17 2004-04-29 Altarex Medical Corporation Therapeutic adjuvant
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20080095790A1 (en) * 2006-10-24 2008-04-24 Perambakam Supriya M Methods of Treating Prostate Cancer
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009126817A2 (en) * 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Ige antibodies for the treatment of cancer
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9023802B2 (en) * 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
DE3650139T2 (de) 1985-07-05 1995-03-09 Hutchinson Fred Cancer Res Verfahren zum reduzieren der immunogenizität und zum induzieren immunologischer toleranz.
EP0234122A3 (en) 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
ATE145727T1 (de) 1989-09-15 1996-12-15 Genetic Systems Corp Hybridoma ct43, das ein antikörper gegen ein mucinepitop von darmkrebs erzeugt
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE4133791A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
GB9606228D0 (en) 1996-03-25 1996-05-29 Secr Defence Apparatus for matrix coating fibres with metal vapour
AU4086397A (en) * 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer

Similar Documents

Publication Publication Date Title
US5869620A (en) Multivalent antigen-binding proteins
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
CA2410604A1 (en) Use of coiled-coil structural scaffold to generate structure-specific peptides
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
Vichier‐Guerre et al. Induction of carbohydrate‐specific antibodies in HLA‐DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use
CA2249746A1 (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
Losman et al. Baboon anti‐idiotype antibodies mimic a carcinoembryonic antigen epitope
RU2001130068A (ru) Антиидиотипические антитела к антителам, которые ингибируют связывание иммуноглобулина с его высокоаффинным рецептором
JP2003514028A (ja) ワクチンとしての抗体の新たな使用
Reinartz et al. Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125
Losman et al. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti‐idiotype antibody
JP2007161700A (ja) メラノーマに対する免疫応答を刺激するためのペプチド
EP0957111B1 (en) Specific binding proteins for treating canine allergy
de Moraes et al. Induction of an immune response through the idiotypic network with monoclonal anti‐idiotype antibodies in the carcinoembryonic antigen system
Lehmann et al. Tumor‐antigen‐specific humoral immune response of animals to anti‐idiotypic antibodies and comparative serological analysis of patients with small‐cell lung carcinoma
Rhodin et al. Characterization of the Streptococcus mutans P1 epitope recognized by immunomodulatory monoclonal antibody 6-11A
Senpuku et al. Identification of a repeated epitope recognized by human serum antibodies in a surface protein antigen of Streptococcus mutans
AU757334B2 (en) Specific binding proteins for treating canine allergy
PL175651B1 (pl) Antyidiotypowe mysie przeciwciała monoklonalne oraz sposób wytwarzania antyidiotypowych przeciwciał monoklonalnych
Ma et al. Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response
Rio et al. Idiotypic restriction of murine monoclonal antibodies to a defined antigenic region of human thyroglobulin
WO2001036485A3 (es) Anticuerpo monocolonal recombinante que reconoce el antigeno ior c2 su uso para el diagnostico y tratamiento de tumores colorectales
Bufe Significance of IgE-binding epitopes in allergic disease
Muller Immunization with peptides
EP0955311A2 (en) Peptide vaccine for canine allergy